Santhera Pharmaceuticals

Santhera announces a full year trading update, as well as an outlook for 2025 and beyond. Some key takeaways are below. ·        Total revenue: CHF 39.1 million (2023: CHF 103.4 million), reflecting solid underlying revenue growth, offset by significant licensing milestones recognized in 2023. ·        Product sales: CHF 14.8 million (2023: CHF 0.8 million), driven by the successful launch of AGAMREE in Germany and Austria. ·        Royalties & milestones: CHF 19.3 million (2023: CHF 99.9 million), with 2023 benefiting from major out-licensing milestones, including agreements with Catalyst Pharmaceuticals in the U.S. and Sperogenix in China. Read our full press release at : #Santhera #theirfutureourfocus #Growth #Pharma #Innovation

🔬💙 More than you can imagine. Time is often taken for granted, but for those living with Duchenne Muscular Dystrophy, time is everything. It’s a race against limitations, yet also a space where possibilities unfold. Every extra year is filled with experiences, emotions, and small yet meaningful victories. The ability to self-feed, play music, hold a loved one’s hand, these are not just moments, they are life itself. This Rare Disease Day, we recognize the power of time, not just time gained, but time truly lived. 💜 Every moment matters. Because time holds more than what you can see. It holds the future, too. #MoreThanYouCanImagine #RareDiseaseDay #Duchenne #EveryMomentMatters #Santhera

Santhera announces an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement for AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD). This milestone makes AGAMREE the first product to receive an agreed federal price in Germany for the treatment of DMD in patients 4 years of age and older, independent of the underlying genetic mutation.   Read our full press release here https://bit.ly/3X05hej #Santhera #theirfutureourfocus

Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Catherine Isted ACMA as Chief Financial Officer (CFO), effective February 24, 2025. Catherine brings over 25 years of leadership experience in life sciences finance, corporate development, and investment banking, making her ideally suited to support Santhera’s continued commercial expansion and next phase of growth.  She succeeds Andrew S., who, after five years at Santhera and financially securing the stable foundations of the company, has decided to step down.  Read our full press release at https://bit.ly/4hwBJNC #Santhera #theirfutureourfocus #CFO #leadership

Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product is not otherwise commercially available. “This distribution agreement with Clinigen, which is complementary to other, earlier announced, partnerships and agreements, will allow Santhera to significantly increase our service level to patients and healthcare professionals through processing individual requests for AGAMREE from geographies in which Santhera is not directly represented or while negotiations with local partners are ongoing,” said Geert Jan van Daal, MD, PhD, Chief Commercial Officer of Santhera. Read our full press release here http://bit.ly/404tUaz.  #santhera #theirfutureourfocus #duchenne #dmd

Santhera Pharmaceuticals (SIX: SANN) announces that China’s National Medical Products Administration (NMPA) has approved AGAMREE® (vamorolone) for use in China in patients aged 4 years and older. "DMD is a devastating condition affecting over 70,000 families in China, and until now, there had been no approved treatment option for patients," said Dario Eklund, CEO of Santhera. "We are delighted that NMPA has approved AGAMREE for the treatment of DMD in China and we look forward to working with our partner Sperogenix Therapeutics as it prepares for the commercialization of the product to ensure DMD patients in China can benefit as soon as possible." Read the full press release here https://bit.ly/3VB5zI1 #Santhera #DMD #Duchenne #theirfutureourfocus #musculardystrophy

Santhera Pharmaceuticals (SIX: SANN) announces that the National Institute for Health and Care Excellence (NICE) has issued guidance that recommends AGAMREE® (vamorolone) for use in the National Health Service (NHS) in England, Wales and Northern Ireland for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older. "DMD is a devastating condition, the most common and severe form of muscular dystrophy, and patients urgently need improved treatment options," said Dario Eklund, CEO of Santhera. "We are delighted that NICE has recommended AGAMREE for patients with DMD, and we are committed to working closely with the NHS to ensure patients can access AGAMREE as quickly as possible." Read the full press release here http://bit.ly/4g4tMyA #Santhera #theirfutureourfocus #DMD #Duchenne

We had an incredible experience on October 17 & 18, presenting at the University of St.Gallen MBA program on the exciting careers in #LifeSciences. Our team at Santhera Pharmaceuticals shared insights on the pharmaceutical world, drug development, and how #Onboarding, #Hiring, #DEI and #LeadingThroughChange are critical for building a diverse and innovative workforce.   It was an honor to engage with these brilliant students and faculty, exchanging ideas and discussing the future of pharma and scientific discovery. A big thank you to Jost Gloor for inviting us to participate, and to everyone who joined us -we’re excited for future collaborations!

Santhera will host a booth at the WMS Congress (8th -12th October | Prague, Czechia) exclusively for healthcare professionals (HCPs).

We are happy to announce that Swissmedic has accepted for review Santhera's marketing authorization application for AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD)! -- “Submission of AGAMREE for DMD to Swissmedic is an important milestone, following approvals from the U.S. FDA, the European Commission in the EU, and the UK MHRA, in addition to acceptance for priority review from China’s NMPA,” commented Shabir Hasham, MD, Chief Medical Officer of Santhera. “We look forward to working closely with Swissmedic to address the high unmet need for improved treatment options for patients suffering from DMD in Switzerland.” Read our full press release here: https://bit.ly/3XT8U6x #Santhera #duchenne #DMD #msculardystrophy #theirfutureourfocus